Role of GST and NAT2 polymorphisms in thyroid cancer

Journal of Endocrinological Investigation

Volumn 31, Issue 11, 2008, Pages 1025-1031

  Hernandez A ^a,b   Xamena, N ^a,b   Surralles J ^a   Galofre P ^c,d   Velazquez A ^a,b   Creus, A ^a   Marcos, Ricard ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Hospital Universari Josep Trueta   (Spain)

Author keywords

GSTM1; GSTP1; GSTT1; NAT2; Thyroid cancer

Indexed keywords

ACYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; RADIOACTIVE IODINE;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; RISK ASSESSMENT; SPAIN; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; URBAN POPULATION;

EID: 59849122452     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345643     Document Type: Article

References (31)

1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. New England J Med 2000, 343: 78-85.
2. Ministerio de Sanidad y Consumo (MSC). La situación del cáncer en España, Publicaciones del Ministerio de Sanidad y Consumo 2005 p. 88.
3. Leenhardt L, Grosclaude P, Cherie-Challine L; Thyroid Cancer Committee. Increased incidence of thyroid carcinome in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004, 14: 1056-60.
4. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res 1991, 51: 1234-41.
5. Robbins J, Merino MJ, Boice JD Jr, et al. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991, 115: 133-47.
6. Ron E, Modan B. Thyroid. In: Schottenfeld D, Fraumeni J, eds. Cancer epidemiology and prevention. Philadelphia: WB Saunders. 1982, 837-54.
7. Kingman S. Thyroid cancer rises after Chemobyl. BMJ 1992, 305: 601-2.
8. Haselkorn T, Stewart SL, Horn-Ross PL. Why are thyroid cancer rates so high in Southeast Asian women living in the United States? The Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 2003, 12: 144-50.
9. Galanti MR, Sparén P, Karlsson A, Grimelius L, Ekbom A. Is residence in areas of endemic goiter a risk factor for thyroid cancer? Int J Cancer 1995, 61: 615-21.
10. Steenland K, Cedillo L, Tucker J, et al. Thyroid hormones and cytogenetic outcomes in backpack sprayers using ethylenebis(dithiocarbamate) (EBCD) fungicides in Mexico. Environ Health Perspect 1997, 105: 1126-30.
11. Wingren GB, Axelson O. Occupational and environmental determinants for benign thyroid disease and follicular thyroid cancer. Int J Occup Environ Health 1997, 3: 89-94.
12. Autrup H. Genetic polymorphisms in human xenobiotic metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000, 464: 65-76.
13. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000, 463: 247-83.
14. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999, 436: 227-61.
15. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2003, 181-182: 457-62.
16. Morari EC, Leite JLP, Granja F, Assumpçao LVM, Ward LS. The null genotype of glutathione S-transfererase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol Biomarkers Prev 2002, 11: 1485-8.
17. Granja F, Morari J, Morari EC, Correa LAC, Assumpçao LVM, Ward LS. GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Lett 2004, 209: 129-37.
18. Canbay E, Dokmetas S, Canbay EI, Sen M Bardakci F. Higher glutathione transferase GSTM1 0/0 genotype frequency in young thyroid carcinoma patients. Curr Med Res Opin 2003, 19: 102-6.
19. Hernández A, Céspedes W, Xamena N, et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett 2003, 190: 37-44.
20. Gaspar J, Rodrigues S, Gil OM, et al. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet Cytogenet 2004, 151: 60-7.
21. Stankov K, Landi S, Gioia-Patricola L, et al. GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients. Cancer Lett 2006, 240: 76-82.
22. Nedelcheva Kristensen V, Andersen TI, Erikstein B, et al. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 1998, 8: 441-7.
23. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9: 29-42.
24. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004, 96: 434-42.
25. Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF. Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis. Cancer Res 1994, 54: 4920-6.
26. Mulders TM, Keizer HJ, Breimer DD, Mulder GJ. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients. Drug Metab Rev 1995, 27: 191-229.
27. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphisms of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998, 8: 27-31.
28. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996, 6: 187-91.
29. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptible factor for lung cancer. Cancer Res 1996, 56: 3961-6.
30. Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 1999, 8: 991-7.
31. Rossing MA, Cushing KL, Voigt LF, Wicklund KG, Daling JR. Risk of papillary thyroid cancer in women in relation to smoking and alcohol consumption. Epidemiology 2000, 11: 49-54.